Bluebird Long Term Debt vs Total Revenue Analysis

BLUE Stock

USD 0.36 0.01 2.86%

Bluebird Bio financial indicator trend analysis is way more than just evaluating Bluebird bio prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bluebird bio is a good investment. Please check the relationship between Bluebird Bio Long Term Debt and its Total Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bluebird bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.

Long Term Debt vs Total Revenue

Long Term Debt vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bluebird bio Long Term Debt account and Total Revenue. At this time, the significance of the direction appears to have weak relationship.

The correlation between Bluebird Bio's Long Term Debt and Total Revenue is 0.35. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Bluebird bio, assuming nothing else is changed. The correlation between historical values of Bluebird Bio's Long Term Debt and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of Bluebird bio are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Long Term Debt i.e., Bluebird Bio's Long Term Debt and Total Revenue go up and down completely randomly.

Correlation Coefficient

0.35

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Long Term Debt

Long-term debt is a debt that Bluebird bio has held for over one year. Long-term debt appears on Bluebird bio balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Bluebird bio balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Total Revenue

Total revenue comprises all receipts Bluebird bio generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from Bluebird Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bluebird bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bluebird bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.At present, Bluebird Bio's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 386.4 M, whereas Tax Provision is projected to grow to (119.7 K).

	2021	2022	2023	2024 (projected)
Total Operating Expenses	529.9M	275.7M	273.8M	373.9M
Cost Of Revenue	38.9M	10.1M	33.5M	36.1M

Total Operating Expenses Cost Of Revenue

Bluebird Bio fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		0.71	0.64	0.96	0.7	0.74	0.56	-0.42	-0.24	0.56	0.78	0.87	0.61	0.6	0.95	0.55	0.13	0.92	0.64	0.38	0.54	0.69	0.69	0.95	-0.07	0.45
Other Current Liab	0.71		0.77	0.68	0.47	0.76	0.31	-0.17	-0.41	0.66	0.36	0.68	0.82	0.81	0.7	0.56	0.01	0.79	0.56	0.71	0.56	0.72	0.72	0.69	-0.15	0.37
Total Current Liabilities	0.64	0.77		0.51	0.26	0.91	0.14	0.16	-0.79	0.85	0.37	0.73	0.97	0.98	0.51	0.89	0.54	0.55	0.72	0.45	0.89	0.93	0.92	0.53	0.42	0.8
Total Stockholder Equity	0.96	0.68	0.51		0.79	0.6	0.67	-0.61	-0.02	0.45	0.78	0.8	0.47	0.46	0.99	0.44	-0.13	0.95	0.51	0.36	0.33	0.55	0.55	0.98	-0.29	0.24
Other Liab	0.7	0.47	0.26	0.79		0.36	0.62	-0.5	0.26	0.24	0.45	0.65	0.23	0.22	0.73	0.18	-0.35	0.82	0.26	0.39	-0.01	0.28	0.3	0.72	-0.39	-0.03
Property Plant And Equipment Net	0.74	0.76	0.91	0.6	0.36		0.15	0.13	-0.7	0.73	0.43	0.81	0.92	0.92	0.59	0.82	0.46	0.64	0.91	0.48	0.83	0.98	1.0	0.62	0.39	0.75
Current Deferred Revenue	0.56	0.31	0.14	0.67	0.62	0.15		-0.78	0.29	0.14	0.71	0.29	0.03	0.03	0.71	0.12	-0.33	0.57	-0.03	0.05	-0.08	0.06	0.1	0.68	-0.48	-0.05
Net Debt	-0.42	-0.17	0.16	-0.61	-0.5	0.13	-0.78		-0.57	0.08	-0.7	-0.03	0.23	0.24	-0.63	0.14	0.62	-0.47	0.22	-0.04	0.36	0.2	0.18	-0.65	0.71	0.37
Retained Earnings	-0.24	-0.41	-0.79	-0.02	0.26	-0.7	0.29	-0.57		-0.61	-0.06	-0.43	-0.8	-0.8	-0.03	-0.82	-0.82	-0.03	-0.58	-0.23	-0.95	-0.74	-0.74	-0.04	-0.79	-0.92
Accounts Payable	0.56	0.66	0.85	0.45	0.24	0.73	0.14	0.08	-0.61		0.3	0.63	0.86	0.86	0.46	0.68	0.35	0.51	0.56	0.1	0.7	0.76	0.73	0.46	0.31	0.6
Cash	0.78	0.36	0.37	0.78	0.45	0.43	0.71	-0.7	-0.06	0.3		0.43	0.26	0.26	0.79	0.4	0.08	0.58	0.33	0.13	0.32	0.38	0.4	0.85	-0.11	0.33
Non Current Assets Total	0.87	0.68	0.73	0.8	0.65	0.81	0.29	-0.03	-0.43	0.63	0.43		0.73	0.72	0.75	0.67	0.28	0.83	0.73	0.35	0.66	0.79	0.78	0.72	0.18	0.58
Non Currrent Assets Other	0.61	0.82	0.97	0.47	0.23	0.92	0.03	0.23	-0.8	0.86	0.26	0.73		1.0	0.47	0.84	0.47	0.56	0.75	0.49	0.88	0.93	0.93	0.48	0.4	0.75
Other Assets	0.6	0.81	0.98	0.46	0.22	0.92	0.03	0.24	-0.8	0.86	0.26	0.72	1.0		0.46	0.85	0.49	0.54	0.75	0.48	0.88	0.94	0.93	0.47	0.41	0.76
Cash And Short Term Investments	0.95	0.7	0.51	0.99	0.73	0.59	0.71	-0.63	-0.03	0.46	0.79	0.75	0.47	0.46		0.41	-0.13	0.94	0.5	0.35	0.33	0.55	0.54	0.98	-0.33	0.21
Common Stock Total Equity	0.55	0.56	0.89	0.44	0.18	0.82	0.12	0.14	-0.82	0.68	0.4	0.67	0.84	0.85	0.41		0.55	0.39	0.62	0.3	0.88	0.82	0.85	0.44	0.57	0.89
Common Stock Shares Outstanding	0.13	0.01	0.54	-0.13	-0.35	0.46	-0.33	0.62	-0.82	0.35	0.08	0.28	0.47	0.49	-0.13	0.55		-0.17	0.46	0.01	0.78	0.54	0.51	-0.09	0.86	0.82
Short Term Investments	0.92	0.79	0.55	0.95	0.82	0.64	0.57	-0.47	-0.03	0.51	0.58	0.83	0.56	0.54	0.94	0.39	-0.17		0.55	0.49	0.32	0.59	0.58	0.91	-0.34	0.17
Non Current Liabilities Total	0.64	0.56	0.72	0.51	0.26	0.91	-0.03	0.22	-0.58	0.56	0.33	0.73	0.75	0.75	0.5	0.62	0.46	0.55		0.34	0.7	0.92	0.91	0.52	0.39	0.6
Other Current Assets	0.38	0.71	0.45	0.36	0.39	0.48	0.05	-0.04	-0.23	0.1	0.13	0.35	0.49	0.48	0.35	0.3	0.01	0.49	0.34		0.31	0.42	0.45	0.38	-0.15	0.2
Other Stockholder Equity	0.54	0.56	0.89	0.33	-0.01	0.83	-0.08	0.36	-0.95	0.7	0.32	0.66	0.88	0.88	0.33	0.88	0.78	0.32	0.7	0.31		0.86	0.86	0.35	0.68	0.95
Total Liab	0.69	0.72	0.93	0.55	0.28	0.98	0.06	0.2	-0.74	0.76	0.38	0.79	0.93	0.94	0.55	0.82	0.54	0.59	0.92	0.42	0.86		0.99	0.56	0.43	0.76
Property Plant And Equipment Gross	0.69	0.72	0.92	0.55	0.3	1.0	0.1	0.18	-0.74	0.73	0.4	0.78	0.93	0.93	0.54	0.85	0.51	0.58	0.91	0.45	0.86	0.99		0.57	0.44	0.78
Total Current Assets	0.95	0.69	0.53	0.98	0.72	0.62	0.68	-0.65	-0.04	0.46	0.85	0.72	0.48	0.47	0.98	0.44	-0.09	0.91	0.52	0.38	0.35	0.56	0.57		-0.29	0.25
Short Term Debt	-0.07	-0.15	0.42	-0.29	-0.39	0.39	-0.48	0.71	-0.79	0.31	-0.11	0.18	0.4	0.41	-0.33	0.57	0.86	-0.34	0.39	-0.15	0.68	0.43	0.44	-0.29		0.8
Common Stock	0.45	0.37	0.8	0.24	-0.03	0.75	-0.05	0.37	-0.92	0.6	0.33	0.58	0.75	0.76	0.21	0.89	0.82	0.17	0.6	0.2	0.95	0.76	0.78	0.25	0.8

Click cells to compare fundamentals

Bluebird Bio Account Relationship Matchups

Bluebird Bio fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.7B	1.8B	593.8M	554.9M	619.2M	1.1B
Other Current Liab	141.6M	180.1M	78.5M	52.0M	9.0M	8.6M
Total Current Liabilities	223.6M	203.6M	153.0M	128.2M	200.1M	114.3M
Total Stockholder Equity	1.3B	1.4B	374.3M	196.3M	194.5M	184.8M
Other Liab	58.0M	48.0M	54.6M	93K	107.0K	101.6K
Property Plant And Equipment Net	337.1M	346.9M	101.2M	291.4M	267.0M	174.1M
Current Deferred Revenue	18.9M	11.6M	2.3M	1.5M	1.4M	1.3M
Net Debt	(136.2M)	(124.7M)	(71.6M)	168.4M	193.6M	203.3M
Retained Earnings	(2.3B)	(2.9B)	(3.7B)	(4.0B)	(4.3B)	(4.0B)
Accounts Payable	43.0M	13.8M	25.9M	14.9M	18.5M	15.1M
Cash	327.2M	317.7M	161.2M	113.0M	221.8M	287.0M
Non Current Assets Total	575.3M	565.7M	257.3M	355.4M	337.5M	352.4M
Non Currrent Assets Other	79.2M	72.8M	53.3M	52.1M	54.3M	35.0M
Other Assets	79.2M	72.8M	53.3M	52.1M	59.9M	33.2M
Cash And Short Term Investments	1.2B	1.3B	396.6M	181.7M	209.0M	198.6M
Common Stock Total Equity	547K	554K	665K	711K	817.7K	431.4K
Common Stock Shares Outstanding	55.2M	62.2M	68.9M	78.6M	192.8M	202.4M
Short Term Investments	531.6M	982.7M	779.2M	833.5M	138.3M	67.3M
Liabilities And Stockholders Equity	1.7B	1.8B	593.8M	554.9M	638.1M	1.1B
Non Current Liabilities Total	218.9M	222.6M	66.5M	230.3M	224.5M	161.3M
Other Current Assets	45.7M	522.2M	25.6M	8.6M	9.9M	9.4M
Other Stockholder Equity	3.6B	4.3B	4.1B	4.2B	4.8B	5.1B
Total Liab	442.4M	426.2M	219.5M	358.6M	424.6M	275.6M
Property Plant And Equipment Gross	337.1M	346.9M	121.6M	313.3M	308.9M	181.3M
Total Current Assets	1.2B	1.2B	336.5M	199.5M	281.7M	267.6M
Accumulated Other Comprehensive Income	(1.9M)	(5.5M)	(2.9M)	(4.1M)	(3.7M)	(3.8M)
Short Term Debt	20.2M	9.7M	46.3M	88.2M	101.5M	106.6M
Common Stock	554K	665K	711K	830K	954.5K	1.0M
Property Plant Equipment	151.2M	162.8M	101.2M	291.4M	335.1M	351.8M
Net Tangible Assets	1.3B	1.3B	368.6M	185.8M	213.7M	203.0M
Net Receivables	12.8M	2.4M	11.4M	10.8M	22.2M	23.3M
Retained Earnings Total Equity	(1.5B)	(2.3B)	(2.9B)	(3.7B)	(3.3B)	(3.2B)
Capital Surpluse	3.4B	3.6B	4.3B	4.1B	4.7B	2.6B
Inventory	(144.3M)	(149.7M)	(108.5M)	(1.4M)	22.9M	24.1M
Non Current Liabilities Other	218.9M	222.6M	93K	92K	105.8K	100.5K
Intangible Assets	14.3M	10.0M	5.6M	4.9M	10.4M	10.8M
Long Term Investments	506.1M	131.5M	122.9M	97.1M	1.4M	0.0

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Bluebird bio is a strong investment it is important to analyze Bluebird Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bluebird Bio's future performance. For an informed investment choice regarding Bluebird Stock, refer to the following important reports:

How To Invest In Bluebird

Details

Is Bluebird Stock a good investment?

Details

What is Bluebird Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bluebird bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.

You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.80)

Revenue Per Share

0.357

Quarterly Revenue Growth

1.337

Return On Assets

(0.36)

Return On Equity

(1.87)

The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bluebird Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bluebird Long Term Debt vs Total Revenue Analysis

Long Term Debt vs Total Revenue

Long Term Debt vs Total Revenue Correlation Analysis

Correlation Coefficient

Long Term Debt

Total Revenue

Bluebird Bio fundamental ratios Correlations

Bluebird Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bluebird Bio fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Other Assets	+ 1.0	Non Currrent Assets Other
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity
Property Plant And Equipment Gross	+ 0.99	Total Liab
Other Assets	+ 0.98	Total Current Liabilities
Total Current Assets	+ 0.98	Total Stockholder Equity

Other Stockholder Equity	- 0.95	Retained Earnings
Common Stock	- 0.92	Retained Earnings
Common Stock Shares Outstanding	- 0.82	Retained Earnings
Common Stock Total Equity	- 0.82	Retained Earnings
Other Assets	- 0.8	Retained Earnings
Non Currrent Assets Other	- 0.8	Retained Earnings